ClinConnect ClinConnect Logo
Search / Trial NCT04865497

Immunogenicity and Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 3 Months to 5 Years Old

Launched by BEIJING ZHIFEI LVZHU BIOPHARMACEUTICAL CO., LTD · Apr 28, 2021

Trial Information

Current as of August 02, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Health infants and children aged from 3 months to 5 years old.
  • Subject or legal representative who consent and has signed written informed consent.
  • Subject and parent/guardian who is able to comply with all study procedures.
  • Subject who did't receive blood products within 30 days ,immune with any live vaccine within 14 days and inactivated vaccine within 7 days before vaccination.
  • Subject who haven't immuned with diarrhea vaccination,3-11 months health infants who haven't immuned with Haemophilus b Conjugate vaccination,or had a history of Hib vaccination before the age of 1 but no history of vaccination after 1 year of age,and the interval between the day of the enrollment and the previous dose is more than one month.
  • Axillary temperature ≤37.0 ℃.
  • Exclusion Criteria:
  • Febrile illness (temperature ≥ 38°C) in the 3 days or in the acute phase of the disease / active period.
  • Subject who have symptoms such as diarrhea, abdominal pain, and pus and bloody stools in the past 3 days.
  • Subject who are allergic to tetanus toxoid.
  • Allergic history after vaccination.
  • Immunodeficiency diseases patients (such as perianal abscess suggests that there may be immunodeficiency in infants and young children) who administered with immunosuppressive agents (≥14 days).
  • Subject who are suffering from serious chronic diseases, cardiovascular disease,liver or kidney disease.
  • Subject with congenital malformations, drug allergies, convulsions, epilepsy, history of craniocerebral trauma, encephalopathy and psychosis, or family history.
  • Subject who diagnosis of thrombocytopenia or other history of coagulopathy may cause intramuscular contraindication.
  • Children with abnormal labor(pregnancy week\<37w,\>42w),birth weight (\<2500g,\>4000g), asphyxia rescue history(Only applicable to 3-5 months old group).
  • Subject who plan to participate in or is in any other drug clinical trial.
  • Any condition that, in the judgment of investigator, may affect trial assessment.

About Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. is a leading biotechnology company based in China, specializing in the research, development, and commercialization of innovative biopharmaceutical products. With a strong focus on vaccines and therapeutic biologics, the company is dedicated to advancing healthcare solutions through cutting-edge technology and rigorous clinical research. Zhifei Lvzhu is committed to enhancing public health by addressing unmet medical needs and improving patient outcomes, while adhering to the highest standards of quality and regulatory compliance in its clinical trials and product development processes.

Locations

Quanzhou, Guangxi, China

Patients applied

0 patients applied

Trial Officials

Du lin, Master

Study Chair

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials